Effects of growth hormone treatment in adults with Prader-Willi syndrome

Growth Hormone and IGF Research

Volumn 23, Issue 3, 2013, Pages 81-87

  Butler, M G ^a   Smith, B K ^b   Lee, J ^c   Gibson, C ^a   Schmoll, C ^d   Moore, W V ^d   Donnelly, J E ^c  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b SOUTHERN ILLINOIS UNIVERSITY EDWARDSVILLE   (United States)

^c UNIVERSITY OF KANSAS   (United States)

^d CHILDREN S MERCY HOSPITAL   (United States)

Author keywords

Body composition; Energy expenditure; Growth hormone treatment; Physical activity; Prader Will syndrome adults

Indexed keywords

GROWTH HORMONE;

ADULT; ARTICLE; BODY COMPOSITION; CLINICAL ARTICLE; DIETARY INTAKE; DRUG EFFICACY; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; ENDURANCE; ENERGY EXPENDITURE; FEMALE; GLYCEMIC CONTROL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; LEG EDEMA; MALE; MUSCLE STRENGTH; PHYSICAL ACTIVITY; PRADER WILLI SYNDROME; PRIORITY JOURNAL; QUALITY OF LIFE; RANGE OF MOTION; TREATMENT DURATION; TREATMENT RESPONSE;

ADIPOSE TISSUE; ADOLESCENT; ADULT; BODY COMPOSITION; ENERGY METABOLISM; EXERCISE; FASTING; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; LIPIDS; MALE; MIDDLE AGED; PRADER-WILLI SYNDROME; PROGNOSIS; QUALITY OF LIFE; YOUNG ADULT;

EID: 84876706642     PISSN: 10966374     EISSN: 15322238     Source Type: Journal    
DOI: 10.1016/j.ghir.2013.01.001     Document Type: Article

References (44)

1. Butler M.G. Prader-Willi syndrome: current understanding of cause and diagnosis. Am. J. Med. Genet. 2009, 35:319-332.
2. Butler M.G., Lee P.D.K., Whitman B.Y. Management of Prader-Willi Syndrome 2006, 1-550. Springer-Verlag, New York. 3rd edition.
3. Cassidy S.B., Driscoll D.J. Prader-Willi syndrome. Eur. J. Hum. Genet. 2009, 17:3-13.
4. Butler M.G. Prader-Willi syndrome: obesity due to genomic imprinting. Curr. Genomics 2011, 12:203-223.
5. Cataletto M., Angulo M., Hertz G., Whitman B. Prader-Willi syndrome: a primer for clinicians. Int. J. Pediatr. Endocrinol. 2011, 1:12.
6. Bittel D.C., Butler M.G. Prader-Willi syndrome: clinical genetics, cytogenetics and molecular biology. Expert Rev. Mol. Med. 2005, 7:1-20.
7. Meaney F.J., Butler M.G. The developing role of anthropologists in medical genetics: anthropometric assessment of the Prader-Labhart-Willi syndrome as an illustration. Med. Anthropol. 1989, 10:247-253.
8. Goldstone A.P., Holland A.J., Hauffa B.P., et al. Recommendations for the diagnosis and management of Prader-Willi syndrome. J. Clin. Endocrinol. Metab. 2008, 93:4183-4197.
9. McCandless S.E. Clinical report-health supervision for children with Prader-Willi syndrome. Pediatrics 2011, 127:195-204.
10. Myers S.E., Carrel A.L., Whitman B.Y., et al. Sustained benefit after 2years of growth hormone on body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome. J. Pediatr. 2000, 137:42-49.
11. Haqq A.M., Stadler D.D., Jackson R.H., et al. Effects of growth hormone on pulmonary function, sleep quality, behavior, cognition, growth velocity, body composition, and resting energy expenditure in Prader-Willi syndrome. J. Clin. Endocrinol. Metab. 2003, 88:2206-2212.
12. Lindgren A.C., Hagenas L., Muller J., et al. Growth hormone treatment of children with Prader-Willi syndrome affects linear growth and body composition favourably. Acta Paediatr. 1998, 87:28-31.
13. Eiholzer U., Gisin R., Weinmann C., et al. Treatment with human growth hormone in patients with Prader-Labhart-Willi syndrome reduces body fat and increases muscle mass and physical performance. Eur. J. Pediatr. 1998, 157:368-377.
14. Carrel A.L., Myers S.E., Whitman B.Y., et al. Growth hormone improves body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome: a controlled study. J. Pediatr. 1999, 134:215-221.
15. Carrel A.L., Moerchen V., Myers S.E., et al. Growth hormone improves mobility and body composition in infants and toddlers with Prader-Willi syndrome. J. Pediatr. 2004, 145:744-749.
16. Lindgren A.C., Lindberg A. Growth hormone treatment completely normalizes adult height and improves body composition in Prader-Willi syndrome: experience from KIGS (Pfizer International Growth Database). Horm. Res. 2008, 70:182-187.
17. Butler M.G., Meaney F.J. Standards for selected anthropometric measurements in Prader-Willi syndrome. Pediatrics 1991, 88:853-860.
18. Mogul H.R., Lee P.D., Whitman B.Y., et al. Growth hormone treatment of adults with Prader-Willi syndrome and growth hormone deficiency improves lean body mass, fractional body fat, and serum triiodothyronine without glucose impairment: results from the United States multicenter trial. J. Clin. Endocrinol. Metab. 2008, 93:1238-1245.
19. Butler M.G., Theodoro M.F., Bittel D.C., et al. Energy expenditure and physical activity in Prader-Willi syndrome: comparison with obese subjects. Am. J. Med. Genet. A 2007, 143:449-459.
20. Lemmer J.T., Ivey F.M., Ryan A.S., et al. Effect of strength training on resting metabolic rate and physical activity: age and gender comparisons. Med. Sci. Sports Exerc. 2001, 33:532-541.
21. Chen K.Y., Sun M., Butler M.G., et al. Development and validation of a measurement system for assessment of energy expenditure and physical activity in Prader-Willi syndrome. Obes. Res. 1999, 7:387-394.
22. Kirk E.P., Donnelly J.E., Smith B.K., et al. Minimal resistance training improves daily energy expenditure and fat oxidation. Med. Sci. Sports Exerc. 2009, 41:1122-1129.
23. Skogerboe K.L., Labbe R.F., Rettmer R.L., et al. Chemiluminescent measurement of total urinary nitrogen for accurate calculation of nitrogen balance. Clin. Chem. 1990, 36:752-755.
24. Livesey G., Elia M. Estimation of energy expenditure, net carbohydrate utilization, and net fat oxidation and synthesis by indirect calorimetry: evaluation of errors with special reference to the detailed composition of fuels. Am. J. Clin. Nutr. 1988, 47:608-628.
25. Jequier E., Acheson K., Schutz Y. Assessment of energy expenditure and fuel utilization. Annu. Rev. Nutr. 1987, 7:187-208.
26. Troiano R.P., Berrigan D., Dodd K.W., et al. Physical activity in the United States measured by accelerometer. Med. Sci. Sports Exerc. 2008, 40:181-188.
27. McKenna S.P. The QoL-AGHDA: an instrument for the assessment of quality of life in adults with growth hormone deficiency. Qual. Life Res. 1999, 8:373-383.
28. Wiren L., Whalley D., McKenna S., et al. Application of a disease-specific, quality-of-life measure (QoL-AGHDA) in growth hormone-deficient adults and a random population sample in Sweden: validation of the measure by rasch analysis. Clin. Endocrinol. 2000, 52:143-152.
29. Jenkinson C., Coulter A., Wright L. Short form 36 (SF36) health survey questionnaire: normative data for adults of working age. BMJ 1993, 306:1437-1440.
30. Baumstarck K., Pelletier J., Aghababian V., et al. Is the concept of quality of life relevant for multiple sclerosis patients with cognitive impairment? Preliminary results of a cross-sectional study. PLoS One 2011, 7:e30627.
31. Bertella L., Mori I., Grugni G., et al. Quality of life and psychological well-being in GH-treated, adult PWS patients: a longitudinal study. J. Intellect. Disabil. Res. 2007, 51:302-311.
32. Brown H., Prescott R. Applied Mixed Models in Medicine 2006, 1-476. John Wiley & Sons, Oxford, England. 2nd edition.
33. Sanchez-Ortiga R., Klibanski A., Tritos N.A. Effects of recombinant human growth hormone therapy in adults with Prader-Willi syndrome: a meta-analysis. Clin. Endocrinol. (Oxf) 2012, 77(1):86-93.
34. Myers S.E., Whitman B.Y., Carrel A.L., Moerchen V., Bekx M.T., Allen D.B. Two years of growth hormone therapy in young children with Prader-Willi syndrome: physical and neurodevelopmental benefits. Am. J. Med. Genet. A 2007, 143(5):443-448.
35. Carrel A.L., Myers S.E., Whitman B.Y., Eickhoff J., Allen D.B. Long-term growth hormone therapy changes the natural history of body composition and motor function in children with Prader-Willi syndrome. J. Clin. Endocrinol. Metab. 2010, 95(3):1131-1136.
36. Siemensma E.P., Tummers-de Lind van Wijngaarden R.F., Festen D.A., et al. Beneficial effects of growth hormone treatment on cognition in children with Prader-Willi syndrome: a randomized controlled trial and longitudinal study. J. Clin. Endocrinol. Metab. 2012, 97(7):2307-2314.
37. Sode-Carlsen R., Farholt S., Rabben K.F., et al. One year of growth hormone treatment in adults with Prader-Willi syndrome improves body composition: results from a randomized, placebo-controlled study. J. Clin. Endocrinol. Metab. 2010, 95:4943-4950.
38. Sode-Carlsen R., Farholt S., Rabben K.F., et al. Body composition, endocrine and metabolic profiles in adults with Prader-Willi syndrome. Growth Horm. IGF Res. 2010, 20:179-184.
39. Sode-Carlsen R., Farholt S., Rabben K.F., et al. Growth hormone treatment in adults with Prader-Willi syndrome: the Scandinavian study. Endocrine 2012, 41:191-199.
40. Angulo M.A., Castro-Magana M., Lamerson M., et al. Final adult height in children with Prader-Willi syndrome with and without human growth hormone treatment. Am. J. Med. Genet. A 2007, 143:1456-1461.
41. Höybye C. Endocrine and metabolic aspects of adult Prader-Willi syndrome with special emphasis on the effect of growth hormone treatment. Growth Horm. IGF Res. 2004, 14:1-15.
42. Eha M. Organ tissue contribution to metabokicr rate. Energy Metabolism, Tissue Determinants and Cellular and Corrolaries 1992, 61-77. Raven Press, New York. J.M. Kinney, N.H. Tucker (Eds.).
43. Sparti A., DeLany J.P., de la Bretonne J.A., Sander G.E., Bray G.A. Relationship between resting metabolic rate and the composition of the fat-free mass. Metabolism 1997, 46(10):1225-1230.
44. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28(7):412-419.